Document Detail

A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
MedLine Citation:
PMID:  23140255     Owner:  NLM     Status:  Publisher    
Palivizumab prophylaxis has been demonstrated to reduce the number of hospitalizations attributable to respiratory syncytial virus in high-risk infants. However, as palivizumab acquisition costs are high, quantifying cost-effectiveness is important. The primary aim of this review was to examine the cost-effectiveness of palivizumab across numerous indications in high-risk infants and to report on factors that may impact outcomes. A systematic literature search was conducted to identify pharmacoeconomic analyzes of palivizumab compared to no prophylaxis for respiratory syncytial virus in infants and young children. A total of 28 articles met inclusion criteria and were subsequently assigned quality scores according to the Quality of Health Economic Studies criteria. Results varied according to perspective, input parameters, outcome measures, populations and base-case and sensitivity analyses. Overall, cost-effectiveness results were inconsistent. Some studies reported favorable outcomes, while others did not, or were inconclusive. Factors to consider in the interpretation of such economic evaluations are discussed.
Julia M Hussman; Abby Li; Bosco Paes; Krista L Lanctôt
Related Documents :
18499855 - Blood flow velocities in the anterior cerebral artery and basilar artery in asphyxiated...
20688615 - Risk factors for cerebral palsy in term birth infants.
23769505 - Risk factors and costs of hospital admissions in first year of life: a population-based...
3061775 - Evolution of periventricular leukomalacia during the neonatal period and infancy: corre...
17584005 - Going to high altitude with a newborn infant.
1161345 - Growth and mineral metabolism in very low birth weight infants. ii. effects of calcium ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-11
Journal Detail:
Title:  Expert review of pharmacoeconomics & outcomes research     Volume:  -     ISSN:  1744-8379     ISO Abbreviation:  Expert Rev Pharmacoecon Outcomes Res     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101132257     Medline TA:  Expert Rev Pharmacoecon Outcomes Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Medical Outcomes and Research in Economics Research Group, Sunnybrook Research Institute, Toronto, ON, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a n...
Next Document:  A novel and efficient ligand-based virtual screening approach using the HWZ scoring function and an ...